BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

IDYA upcoming catalysts

IDEAYA Biosciences: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 0 FDA event(s). Subscribe to IDYA (.ics).

Drugs: IDE196, Crizotinib, Pembrolizumab, Ipilimumab, Nivolumab, Dacarbazine, Binimetinib

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01-15 est.P2/P3IDEAYA Biosciences IDYANCT05987332 IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaMetastatic Uveal Melanomaactive not recruiting420
2027-01-29 est.P1/P2IDEAYA Biosciences IDYANCT03947385 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsMetastatic Uveal Melanoma; Cutaneous Melanoma; Colorectal Cancer; Other Solid Tumorsrecruiting336

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
No FDA decision events in this window.

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.